Artiklar

{{ window.visitor.ipAccess.corporateClient.name }}
Welcome to our Corporate client solution

Your IP is registered with the company mentioned above and provides access to Life Science Sweden.
Click here to go to sign-up

Sortering: Sida Sida av 1

Symphogen buys tumor blocking technology
Januar 29 2009
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.

Resultat per sida: Sida Sida av 1

BREAKING

{{ article.headline }}

0.078|instance-web04